Use of multiple biomarkers for evaluation of anthracycline-induced cardiotoxicity in patients with acute myeloid leukemia

Abstract

The article deals with the assessment of cardiac toxicity of anthracycline treatment with six biomarkers of cardiac injury: myoglobin, creatine kinase MB (CK-MB mass), cardiac troponin T (cTnT), cardiac troponin I (cTnI), heart-type fatty acid binding protein (H-FABP), glycogen phosphorylase BB (GPBB). GPBB could be a new promising marker for detection of anthracycline-related cardiotoxicity and probably superior to cardiac troponins.

Keywords

• cardiac biomarkers
• glycogen phosphorylase BB
• cardiotoxicity
• anthracyclines
• chemotherapy
• acute myeloid leukemia